MaaT Pharma, a Lyon, France-based clinical stage company, raised an additional €7.35m in ($8.7m) in Series B financing round, bringing the total raised in this round to €25.35m.
The round was led by PSIM Fund, managed by Bpifrance on behalf of the French State, with participation from SkyViews Life Science and Celeste Management. In February, the company announced the initial closing of an €18m Series B financing round, led by US investor SymBiosis, with participation from Seventure Partners, Crédit Mutuel Innovation, and Biocodex.
Led by Hervé Affagard, CEO and Co-founder, MaaT Pharma leverages a microbiome restoration biotherapeutics platform to develop drugs that harness the rich diversity of the gut microbiome to improve overall survival in blood cancers and Graft-versus-Host Disease (GvHD).
The company intends to use the funds to advance its innovative fermentation production platform for the development of next-generation, large-scale, fully controlled microbiome ecosystem therapeutics. By leveraging MaaT Pharma’s GutPrint® computational data science platform, the new industrial fermentation platform will enable to develop and manufacture both “standard” high-richness, high-diversity fermented product MaaT034, and a pipeline of indication-specific candidates. In particular, the fermentation technology supports pipeline extension towards solid tumors indications, for combination with immunotherapy. The resulting new product candidates will complement the company’s donor-derived lead products MaaT013 (enema) and MaaT033 (oral formulation) for the treatment of GvHD and liquid tumors.
The funding will also support the production of MaaT013 to meet the demand from clinicians wanting to access the product for the treatment of their GvHD patients with no other therapeutic options; this compassionate use is permitted by the French regulator under an “ATUn” program.